After 7 years of international collaboration, we are delighted to be sharing with you the CRASH-3 trial results.
The CRASH-3 trial is the first evidence of a drug which can prevent death following Traumatic Brain Injury (TBI). Tranexamic Acid (TXA) is a safe, low cost, and widely available drug which could prevent deaths from TBI by as much as 20% depending on severity of the injury.
Listen below to hear more about CRASH-3 and how TXA could be a potentially life-saving treatment. Pam Foley suffered a TBI after falling off her bike and was asked to participate in the CRASH-3 trial - hear her story below.
“Why wouldn’t you give it?”– Prof Tony Belli, trauma neurosurgeon and co-investigator on the CRASH-3 trial discussing the benefits of TXA for patients with TBI.
Find out more from the CRASH-3 study publication in The Lancet and follow the links below for news articles and podcasts:
UK press releases:
- BBC News
- The Guardian
- The Times
- The Independent
- ITV News
- The Daily Mail
- BBC Radio 4 Today programme (at 53:30)
- BBC World Service - Health Check
- The Irish Times
- Express and Star
- Local news- Bournemouth
- Local news- York
- LSHTM article
- Medical Daily
International press releases:
- National Institute for Health Research (NIHR) Signal
- St. Emlyn's
- Pulmonary and Critical Care Medicine
- The Skeptic's Guide to EM
- EM Nerd
- NHS 'Behind the headlines'
- Speciality Medical Dialogues
- Science Debate
- University of Birmingham News
- Sciencenet, China
Interested to know how TXA works in the body? Our friendly canines can explain it to you…
For further explanation of the rationale, statistics and significance of the CRASH-3 trial results watch the below presentations as given by Prof Ian Roberts along with the accompanying slides below.
Prof Roberts presenting at the World Congress of Intensive Care, Melbourne:
Prof Ian Roberts explaining the CRASH-3 trial results in Malaysia:
For more information about the trial and for the results presented in animation form please watch the video below.